Publications by authors named "J M MacDougall"
Infliximab is an anti-tumor necrosis factor agent used to treat rheumatologic disease. Evidence on the safety of switching to biosimilars and the associated risk factors for flares/loss of disease control within rheumatology is limited. The primary objective is to evaluate nonmedical switches from reference infliximab to biosimilars in rheumatology on risks and level of disease control.
View Article and Find Full Text PDFArticle Synopsis
- The SIERRA trial aimed to improve outcomes for older patients with relapsed or refractory acute myeloid leukemia (RR AML) by comparing a new treatment, I-apamistamab, against standard care before bone marrow transplant.
- The study involved 153 patients, with results showing a significantly higher durable complete remission (dCR) rate of 17.1% for the I-apamistamab group compared to 0% for the conventional care group.
- Although the overall survival rates were similar between the two groups, the I-apamistamab regimen exhibited more promise for achieving long-lasting remission with similar levels of severe side effects.
As terahertz (THz) and sub-THz region electromagnetic waves are becoming vital for industrial applications such as 5G wireless communication, so too are THz and sub-THz wave absorbing materials. Herein, we report the optical properties of monoclinic zirconia (m-ZrO) nanoparticles in these frequency regions, with different crystalline sizes. The crystalline sizes of the three samples, measured by transmission electron microscopy, are 93 ± 23 nm (denoted 1), 28 ± 14 nm (denoted 2) and 2.
View Article and Find Full Text PDFObjective: To report a case of a patient with Turner syndrome (TS) mosaicism and polycystic ovarian syndrome (PCOS), who underwent successful ovarian stimulation, oocyte retrieval, and cryopreservation.
Design: Case report.
Subjects: A female patient with mosaic TS (45,X [24%]/46,XX [76%]) and a paternally inherited balanced reciprocal translocation t(2:6) diagnosed with PCOS.